NCT07477639 Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis Status RECRUITING Phase PHASE1/PHASE2
NCT07225985 Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma Status RECRUITING Phase PHASE1/PHASE2
NCT07189065 A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma Status RECRUITING Phase PHASE2
NCT07169565 Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia Status NOT_YET_RECRUITING Phase PHASE1
NCT07139873 A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) Status RECRUITING Phase PHASE3
NCT07003464 Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study Status NOT_YET_RECRUITING Phase PHASE2
NCT06970743 A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors Status RECRUITING Phase PHASE3
NCT06961500 Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A Status NOT_YET_RECRUITING Phase PHASE2
NCT06911502 A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) Status RECRUITING Phase PHASE3
NCT06854003 BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Status RECRUITING Phase PHASE2
NCT06846671 A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Status RECRUITING Phase PHASE3
NCT06761911 BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma Status NOT_YET_RECRUITING Phase PHASE4
NCT06757894 Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma Status NOT_YET_RECRUITING Phase PHASE2
NCT06557330 MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma Status NOT_YET_RECRUITING Phase PHASE2
NCT06554600 A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Status RECRUITING Phase PHASE2
NCT06522737 A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Status RECRUITING Phase PHASE3
NCT06496308 Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment Status RECRUITING Phase PHASE3
NCT06483048 MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Status RECRUITING Phase PHASE1
NCT06465446 A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma Status NOT_YET_RECRUITING Phase PHASE3